Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells

Blood

Volumn 94, Issue 4, 1999, Pages 1401-1408

  Byrd, John C ^a   Shinn, Charlotte ^b   Ravi, Rajani ^b   Willis, Carl R ^b   Waselenko, Jamie K ^b   Flinn, Ian W ^b   Dawson, Nancy A ^b   Grever, Michael R ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEPSIPEPTIDE; FR 901228; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ARTICLE; B CELL LEUKEMIA; CELL CULTURE; CELL GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; DRUG MECHANISM; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033566643     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.4.1401     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47:5, 1997
2. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M: Prognosis in chronic lymphocytic leukemia: A multivariate regression analysis of 325 untreated patients. Blood 69:929, 1987
3. Rai KR, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer CA: A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB SWOG, CTG/NCI-C and ECOG Inter-Group Study. Blood 88:141a, 1996 (abstr, suppl 1)
4. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenhauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P: P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell lymphocytic leukemia. Blood 85:1580, 1995
5. El Rouby S, Thomas A, Costin D, Ros enberg CR, Potmesil M, Silber R, Newcomb E: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
6. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
7. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 mutation and bcl-2/bax proteins in drug resistance. Oncogene 12:1055, 1996
8. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating MJ: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of bcl-2 and bax. J Immunol 156:2624, 1996
9. Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J: Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87:1056, 1996
10. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV: Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukemia cells in vitro Br J Haematol 85:439, 1993
11. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin-4 protects chronic lymphocytic leukemia B-cells from death by apoptosis and upregulates bcl-2 expression. J Exp Med 176:1319, 1992
12. Kip1 in chronic B-cell lymphocytic leukemia. Blood 91:4694, 1998
13. Kip1 cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation. J Immunol 158:3054, 1997
14. Morrison VA: The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25:98, 1998
15. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990, 1996
16. Yewdell JW, Gannon JV, Lane DP: Monoclonal antibody analysis of p53 expression on normal and transformed cells. J Virol 59:444, 1986
17. Byrd JC, Shinn C, Waselenko J, Fuches EJ, Flinn IW, Diehl LF, Sausville E, Grever MR: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence upon functional p53. Blood 92:3804, 1998
18. Cheson BD: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431, 1995
19. Byrd JC, Hargis JB, Kester KE, Hospenthal D, Knutson SW, Diehl LF: Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 49:135, 1995
20. Byrd JC, Houde-McGrail LL, Hospenthal DR, Howard RS, Dow N, Diehl LF: Herpes virus infections in patients with low-grade lymphoproliferative disorders following treatment with fludarabine: Results of a natural history study Br J Haematol (in press)
21. Byrd JC, Shinn CA, Bedi A, Waselenko JK, Flinn IW, Diehl LF, Sausville E, Grever MR: UCN-01: A promising new agent for B-cell chronic lymphocytic leukemia that induces apoptosis independent of p53 status. Blood 90:306b, 1997 (abstr, suppl 1, part 2)
22. Ueda H, Nakajima H, Hori Y, Fujita T, Mishimura M, Goto T, Okuhara MF: Depsipeptide: A novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. Taxonomy, fermentation, isolation, physico-chemica 1, and biological properties, and antitumor activity. J Antibiotics 47:301, 1994
23. Shigematsu N, Ueda H, Takase S, Tanaka H: Depsipeptide: A novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. Structural determination. J Antibiotics 47:311, 1994
24. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M: Action of Depsipeptide, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Bioltech Biochem 58:1579, 1994
25. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K: Depsipeptide: A novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. Antitumor activities on experimental tumors in mice. J Antibiotics 47:315, 1994
26. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126, 1998